GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (OTCPK:CNTGF) » Definitions » Loans Receivable

CNTGF (Centogene NV) Loans Receivable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Centogene NV Loans Receivable?

Centogene NV's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.


Centogene NV Loans Receivable Historical Data

The historical data trend for Centogene NV's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV Loans Receivable Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Centogene NV Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Centogene NV Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Centogene NV Loans Receivable Related Terms

Thank you for viewing the detailed overview of Centogene NV's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Centogene NV Business Description

Traded in Other Exchanges
Address
Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.